The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

✍ Scribed by Brian Henry; Susan H. Fox; David Peggs; Alan R. Crossman; Jonathan M. Brotchie

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 152 KB
• Volume: 14
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7